Y-mabs Therapeutics share price today

(YMAB)

Y-mabs Therapeutics share price is $6.31 & ₹546.40 as on 15 Jan 2025, 2.30 'hrs' IST

$6.31

▲

-0.19

(-2.92%)

Market is closed - opens 8 PM, 15 Jan 2025

View live Y-mabs Therapeutics share price in Dollar and Rupees. Guide to invest in Y-mabs Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Y-mabs Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Y-mabs Therapeutics share price movements

Today's Low: $6.02
Today's High: $6.59
$6.31
4.6%
Downside
Day's Volatility :8.65%
Upside
4.25%
52 Weeks Low: $6.24
52 Weeks High: $20.90
$6.31
1.11%
Downside
52 Weeks Volatility :70.14%
Upside
69.81%

Y-mabs Therapeutics Returns

Period	Y-mabs Therapeutics Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-55.81%	-8.6%	0.0%
6 Months	-48.33%	-4.6%	0.0%
1 Year	-32.22%	0.7%	0.0%
3 Years	-41.23%	5.5%	-18.2%

Y-mabs Therapeutics Key Statistics

in dollars & INR

Previous Close	$6.5
Open	$6.59
Today's High	$6.59
Today's Low	$6.02
Market Capitalization	$308.6M
Today's Volume	$673.4K
52 Week High	$20.9
52 Week Low	$6.02
Revenue TTM	$84.6M
EBITDA	$-23.4M
Earnings Per Share (EPS)	$-0.54
Profit Margin	-28.22%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-24.78%

How to invest in Y-mabs Therapeutics from India?

It is very easy for Indian residents to invest directly in Y-mabs Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Y-mabs Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Y-mabs Therapeutics or YMAB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Y-mabs Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Y-mabs Therapeutics shares which would translate to 0.137 fractional shares of Y-mabs Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Y-mabs Therapeutics, in just a few clicks!

Returns in Y-mabs Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Y-mabs Therapeutics investment value today

Current value as on today

₹70,274

Returns

₹29,726

(-29.73%)

Returns from Y-mabs Therapeutics Stock

₹34,202 (-34.2%)

Dollar Returns

₹4,476 (+4.48%)

Indian investors sentiment towards Y-mabs Therapeutics

200%

Period: Oct 16, 2024 to Jan 14, 2025. Change in 30 Days versus previous period

Search volume for Y-mabs Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 15, 2025. 200% more investors are searching Y-mabs Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Y-mabs Therapeutics

Paradigm Biocapital Advisors LP
9.12%
BlackRock Inc
6.75%
Sofinnova Ventures
4.90%
Vanguard Group Inc
4.54%
Polar Capital Holdings PLC
4.09%
Cormorant Asset Management, LLC
3.24%

Analyst Recommendation on Y-mabs Therapeutics

Buy

76%Buy

15%Hold

7%Sell

Based on 13 Wall street analysts offering stock ratings for Y-mabs Therapeutics(by analysts ranked 0 to 5 stars)

Based on 13 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Y-mabs Therapeutics

What analysts predicted

Upside of 222.72%

Target:

$20.36

Current:

$6.31

Insights on Y-mabs Therapeutics

Price Movement
In the last 7 days, YMAB stock has moved down by -15.0%
Decreasing Revenue
Revenue is down for the last 2 quarters, 22.79M → 18.46M (in $), with an average decrease of 19.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -9.24M → -6.99M (in $), with an average increase of 32.2% per quarter
YMAB vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 33.5% return, outperforming this stock by 66.1%
YMAB vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 73.9% return, outperforming this stock by 120.3%
Price to Sales
ForYMAB every $1 of sales, investors are willing to pay $3.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $15.6 for every $1 of sales.

Y-mabs Therapeutics Technicals Summary

Sell

Neutral

Buy

Y-mabs Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Y-mabs Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Y-mabs Therapeutics Inc.	-34.48%	-48.33%	-32.22%	-41.23%	-80.29%
Biontech Se	-0.42%	31.54%	14.23%	-32.79%	242.8%
Regeneron Pharmaceuticals, Inc.	-1.1%	-33.96%	-23.52%	17.29%	85.75%
Vertex Pharmaceuticals Incorporated	-11.69%	-15.36%	-5.51%	78.89%	75.28%
Alnylam Pharmaceuticals, Inc.	5.85%	7.6%	37.75%	85.55%	117.36%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Y-mabs Therapeutics Inc.	NA	NA	NA	-0.63	-0.25	-0.12	NA	2.07
Biontech Se	160.8	NA	0.04	-3.2	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.24	17.24	1.06	44.97	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.08	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Y-mabs Therapeutics Inc.	Buy	$308.6M	-80.29%	NA	-28.22%
Biontech Se	Buy	$27.3B	242.8%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$77.5B	85.75%	17.24	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$106.5B	75.28%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$33.3B	117.36%	NA	-15.86%

About Y-mabs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Organization	Y-mabs Therapeutics
Employees	100
CEO	Mr. Michael Rossi
Industry	Health Technology

Management People of Y-mabs Therapeutics

Name	Title
Mr. Michael Rossi	CEO, President & Director
Mr. Thomas Gad	Founder, Chief Business Officer & Vice Chairman
Ms. Susan Smith	Senior VP & Chief Commercial Officer
Mr. Peter P. Pfreundschuh CPA	CFO & Treasurer
Mr. Joris Wiel Jan Wilms	Senior VP & COO
Dr. Torben Lund-Hansen M.Sc., Ph.D.	Senior VP & CTO
Ms. Courtney Dugan	Vice President of Investor Relations
Dr. Vignesh Rajah M.B.A., MBBS	Senior VP & Chief Medical Officer
Dr. Norman D. LaFrance FACNP, FACP, M.D.	Chief Development Officer

Important FAQs about investing in Y-mabs Therapeutics from India :

What is Y-mabs Therapeutics share price today?

Y-mabs Therapeutics share price today stands at $6.31, Open: $6.59 ; Previous Close: $6.50 ; High: $6.59 ; Low: $6.02 ; 52 Week High: $20.90 ; 52 Week Low: $6.24. The stock opens at $6.59, after a previous close of $6.50. The stock reached a daily high of $6.59 and a low of $6.02, with a 52-week high of $20.90 and a 52-week low of $6.24.

Can Indians buy Y-mabs Therapeutics shares?

Yes, Indians can invest in the Y-mabs Therapeutics (YMAB) from India.

With INDmoney, you can buy Y-mabs Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Y-mabs Therapeutics at zero transaction cost.

How can I buy Y-mabs Therapeutics shares from India?

It is very easy to buy Y-mabs Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Y-mabs Therapeutics be purchased?

Yes, you can buy fractional shares of Y-mabs Therapeutics with INDmoney app.

What are the documents required to start investing in Y-mabs Therapeutics stocks?

To start investing in Y-mabs Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.